TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28503770
Drug: Intranasal crushed
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal crushed extended release levetiracetam (LEVCER) 30 mg/kg
Study: 22682875
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg CoQ10 + 300 IU vitamin E
Study: 21347907
Drug: Standard behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard behavioral group therapy
Study: 21347907
Drug: Smoker control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoker control group without treatment
Study: 17311241
Drug: New treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatment for stress urinary incontinence
Study: 7941195
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg SIN-1
Study: 7941195
Drug: P/P (papaverine
Approvals — FDA: no, EMA: no, PMDA: no
Description: P/P (papaverine 15 mg/mL and phentolamine 0.5 mg/mL)
Study: 22917813
Drug: Enzastaurin (1125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin (1125 mg on Day 1 followed by 500 mg daily)
Study: 12957426
Drug: Short-term vitamin
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term vitamin C administration (3 g intravenous infusion)
Study: 12957426
Drug: Long-term vitamin
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term vitamin C treatment (2 g daily for 3 months)
Study: 12957426
Drug: Long-term vitamin
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term vitamin C treatment (2 g daily for 2 years)
Study: 12957426
Drug: Short-term vitamin
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term vitamin C infusion (3 g intravenous infusion)
Study: 12957426
Drug: Short-term vitamin
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term vitamin C treatment (3 g intravenous infusion)
Study: 1522084
Drug: Miconazole varnish
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole varnish (single-dose application)
Study: 1522084
Drug: Miconazole gel
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole gel (applied three times/day for 15 days)
Study: 30106266
Drug: Ifenprodil (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifenprodil (60 mg per day for 3 months)
Study: 30106266
Drug: Control (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (600 mg ascorbic acid and calcium pantothenate per day for 3 months)
Study: 25253123
Drug: Prior use
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior use of inhaled steroids
Study: 20467288
Drug: Raltegravir-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir-based therapy
Study: 20467288
Drug: Ritonavir-boosted protease
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted protease inhibitor-based therapy
Study: 18638004
Drug: Mirodenafil 50
Normalized name: Mirodenafil
DrugBank: Mirodenafil (DB11792)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirodenafil 50 mg
Study: 10486418
Drug: Amiodarone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (300 mg intravenous)
Study: 8666569
Drug: Buspirone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (15 to 45 mg/day)
Study: 3899666
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 20 mg/day for 1 yr
Study: 55529
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no further treatment)
Study: 26524933
Drug: Epinephrine (0.33
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (0.33 mg/L) added to saline irrigation fluid
Study: 20205481
Drug: Subcutaneous rehydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous rehydration therapy (SCRT)
Study: 20205481
Drug: Intravenous rehydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rehydration therapy (IVRT)
Study: 16022023
Drug: Adjunctive local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive local delivery of extracts from Centella asiatica and Punica granatum
Study: 16022023
Drug: Standard supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard supportive periodontal therapy (SPT)
Study: 12446187
Drug: Cheese containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cheese containing Lactobacillus rhamnosus GG and Lactobacillus rhamnosus LC 705, 5 x 15 g per day for 3 weeks
Study: 8076229
Drug: Midazolam (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.07 mg.kg‐1 for <65 years, 0.06 mg.kg‐1 for ≥65 years)
Study: 8076229
Drug: Diazepam (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.15 mg.kg‐1 for <65 years, 0.11 mg.kg‐1 for ≥65 years)
Study: 2531570
Drug: Calcipotriol 25
Normalized name: calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcipotriol 25 micrograms/g
Study: 2531570
Drug: Calcipotriol 50
Normalized name: Calcipotriol 50 microgram/g cutaneous cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 50 micrograms/g
Study: 2531570
Drug: Calcipotriol 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 100 micrograms/g
Study: 2531570
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with calcipotriol ointment
Study: 26324362
Drug: XELOX (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOX (oxaliplatin 130 mg/m² on day 1 and capecitabine 1,000 mg/m² twice daily on days 1 to 14 every 3 weeks for 6 months)
Study: 23799929
Drug: Subcutaneous nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous nerve stimulation (SQS) plus optimized medical management
Study: 20466200
Drug: High-dose N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose N-acetylcysteine (2 x 1,200 mg/day for 48 h)
Study: 18419497
Drug: Planned treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Planned treatment interruption with nevirapine
Study: 18419497
Drug: Planned treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Planned treatment interruption with efavirenz
Study: 18419497
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy (control group)
Study: 17206976
Drug: Early administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early administration of atosiban
Study: 17206976
Drug: Standard administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard administration of atosiban
Study: 17206976
Drug: Early atosiban
Normalized name: atosiban
DrugBank: Atosiban (DB09059)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Early atosiban administration
Study: 17206976
Drug: Standard atosiban
Normalized name: atosiban
DrugBank: Atosiban (DB09059)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Standard atosiban administration
Study: 12545081
Drug: RTV/IDV (100/400
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTV/IDV (100/400 mg bid)
Study: 12545081
Drug: IDV (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDV (800 mg tid)
Study: 8781321
Drug: 520-kcal diet
Normalized name: CIDER VINEGAR DIET FORMULA CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 520-kcal diet with less than 2 g fat/d
Study: 8781321
Drug: 900-kcal diet
Normalized name: CIDER VINEGAR DIET FORMULA CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900-kcal diet with 30 g fat/d (including one 10-g fat meal)
Study: 1596317
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg Methylprednisolone
Study: 1596317
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml NaCl 0.9%
Study: 25275230
Drug: Continuous jejunal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous jejunal infusion of levodopa-carbidopa intestinal gel
Study: 25275230
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral levodopa therapy
Study: 23207562
Drug: NG solution
Normalized name: Cleansing Solution
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG solution wrapping (Group II, N=11)
Study: 23207562
Drug: 2 cc
Normalized name: Bag Reclosable 2 cc 2X8
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 cc NG injection (Group III, N=10)
Study: 23207562
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injection (Group IV, N=10)
Study: 15752663
Drug: Chlormadinone acetate
Normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormadinone acetate (10 mg once a day from day 5 to day 25)
Study: 15752663
Drug: Chlormadinone acetate
Normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormadinone acetate (10 mg once a day from day 8 to day 25)
Study: 12228784
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) plus ASA
Study: 1978689
Drug: Tryptophan (TRP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tryptophan (TRP), up to 6 g/day, administered for 25-35 days
Study: 686893
Drug: Prophylactic oral
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic oral neomycin and erythromycin base
Study: 31673828
Drug: Chronic peritoneal
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic peritoneal dialysis with concurrent colostomy
Study: 24938534
Drug: Selenium-enriched yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium-enriched yeast (SY) 200 or 285 μg/day
Study: 24938534
Drug: Selenium-enriched yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium-enriched yeast (SY) high-dose
Study: 24938534
Drug: Selenium-enriched yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium-enriched yeast (SY) low-dose
Study: 24938534
Drug: Selenomethionine (SeMet)
Normalized name: selenomethionine
DrugBank: Selenomethionine (DB11142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selenomethionine (SeMet) 200 μg/day
Study: 17895968
Drug: Leading sports
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leading sports drink (G)
Study: 8220939
Drug: misoprostol 400-800
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: misoprostol 400-800 micrograms daily
Study: 3806169
Drug: Adjuvant methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant methotrexate (MTX) started at 40 mg/m2 and escalated by 10 mg/m2 weekly, with four doses preoperatively, four doses postoperatively before radiation therapy, and eight doses post-radiation therapy.
Study: 31138085
Drug: NfL levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NfL levels (measured using Single Molecule Array technology)
Study: 24191893
Drug: 750 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg/day probucol plus 160 mg/day valsartan
Study: 24191893
Drug: 160 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg/day valsartan
Study: 20601912
Drug: Silicone hydrogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone hydrogel lenses with multipurpose solutions
Study: 12946081
Drug: Manual‐assisted cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual‐assisted cognitive behaviour therapy (MACT)
Study: 1303775
Drug: Cetirizine (Zyrtec
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (Zyrtec 10 mg/day)
Study: 2864486
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg zinc per day as zinc acetate
Study: 3623260
Drug: Calcium (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (375 mg/day) and vitamin D (1,200 IU/day) supplementation
Study: 19236727
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg (Eso20)
Study: 19236727
Drug: Pectin‐based raft‐forming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectin‐based raft‐forming agent (PRA)
Study: 16434738
Drug: Xylitol 6.88
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol 6.88 g/day (G3)
Study: 16434738
Drug: Xylitol 10.32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol 10.32 g/day (G4)
Study: 10679534
Drug: Active intervention
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active intervention (asthma education and optimisation of drug therapy)
Study: 9333148
Drug: Zidovudine alone
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine alone or in combination with the immunogen
Study: 8222665
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g ascorbic acid taken 1/2 hour before OC intake
Study: 8222665
Drug: Combination monophasic
Normalized name: Monobasic Potassium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination monophasic oral contraceptive without ascorbic acid
Study: 2429800
Drug: Cimetidine, 4
Normalized name: Cimetidine, 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 4 mg/kg, plus placebo
Study: 2429800
Drug: Chlorpheniramine, 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine, 0.1 mg/kg, plus placebo
Study: 29727369
Drug: High-illuminance blue
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-illuminance blue light therapy
Study: 20214175
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate 1%/benzoyl peroxide 5% gel (BPO/C)
Study: 20214175
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate 1.2%/tretinoin 0.025% gel (T/C)
Study: 10626316
Drug: Risk factor-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk factor-based cognitive behavioral therapy
Study: 10626316
Drug: Refusers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refusers of therapy
Study: 4028625
Drug: Transdermal therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal therapeutic system of scopolamine (TTS-S)
Study: 4028625
Drug: Transdermal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal placebo (TD-P)
Study: 7288807
Drug: (+)-isomer of
Normalized name: hexadecene (mixed isomers)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+)-isomer of tranylcypromine at doses below 3 mg/day
Study: 20385894
Drug: Infiltration, physiotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration, physiotherapy, or medication
Study: 17368065
Drug: Medical product
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL LIQUID [Apollo Medical Products Disinfecting Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical product (with or without LNAA supplements)
Study: 15837702
Drug: OXAFAFU high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXAFAFU high dose (hd)
Study: 15837702
Drug: OXAFAFU low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXAFAFU low dose (ld)
Study: 15837702
Drug: OXAFAFU (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXAFAFU (both doses)
Study: 8073391
Drug: Heparin sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin sodium (HEP)
Study: 2563788
Drug: Hepatitis-B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis-B vaccine + 7 monthly injections of HB immunoglobulin (HBIg)
Study: 2563788
Drug: Hepatitis-B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis-B vaccine + 1 HBIg injection at birth
Study: 2563788
Drug: Hepatitis-B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis-B vaccine only
Study: 2563788
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for both vaccine and HBIg
Study: 31006122
Drug: Intra-articular triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular triamcinolone acetonide (20 mg in both tarsocrural joints, total 40 mg/horse)
Study: 31006122
Drug: Intramuscular triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular triamcinolone acetonide (40 mg)
Study: 27060379
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine (Danish strain 1331 SSI)
Study: 22969980
Drug: PEG 4000
Normalized name: PEG 4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG 4000 (20 g/day)
Study: 22969980
Drug: Lactulose (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (15 ml/day)
Study: 1775598
Drug: Fluoxetine at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine at 20 mg/day for at least 8 weeks
Study: 25349205
Drug: AST-120 (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-120 (9 g/d)
Study: 25208597
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 20 mg tadalafil
Study: 25208597
Drug: Continuous dose
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous dose of 5 mg tadalafil each morning for seven consecutive days
Study: 22647399
Drug: TAU plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU plus cognitive behavioral therapy sessions, psycho-educational sessions for family members, and case management
Study: 17900265
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ebastine
Study: 1827340
Drug: Intravenous sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sufentanil (IVS)
Study: 518806
Drug: Oral preparation
Normalized name: Iron bivalent, oral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral preparation of dichloralphenazone and paracetamol (Paedosed)
Study: 518806
Drug: i.m. morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. morphine and atropine
Study: 31644357
Drug: pTVG-HP co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: pTVG-HP co-administered intradermally with 200 μg GM-CSF adjuvant
Study: 31644357
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg GM-CSF alone
Study: 25930144
Drug: SG1002 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: SG1002 (400 mg)
Study: 25930144
Drug: SG1002 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: SG1002 (400 mg and 800 mg)
Study: 25930144
Drug: SG1002 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: SG1002 (all doses)
Study: 23672597
Drug: Jiangtang Xiaozhi
Normalized name: Jianghuang
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiangtang Xiaozhi (3 capsules three times daily for 16 weeks)
Study: 15482360
Drug: 0.5 microg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 microg/kg/min GTN infusion
Study: 11490238
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg exisulind twice daily for 12 months
Study: 17405568
Drug: ACE-inhibitors
Normalized name: Gastric inhibitory polypeptide
DrugBank: Gastric inhibitory polypeptide (DB15217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-inhibitors
Study: 2718479
Drug: Clidinium bromide
Normalized name: Clidinium Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clidinium bromide 5 mg + Magnesium citrate
Study: 2718479
Drug: Clidinium bromide
Normalized name: Clidinium Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clidinium bromide 5 mg + Placebo liquid
Study: 2718479
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule + Magnesium citrate
Study: 2718479
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule + Placebo liquid
Study: 340138
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg mefenamic acid
Study: 340138
Drug: 32.5 mg
Normalized name: phenol 32.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32.5 mg dextropropoxyphene hydrochloride plus 325 mg paracetamol
Study: 21148048
Drug: Arterolane maleate
Normalized name: maleate
DrugBank: Arterolane (DB19027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arterolane maleate 50 mg
Study: 21148048
Drug: Arterolane maleate
Normalized name: maleate
DrugBank: Arterolane (DB19027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arterolane maleate 100 mg
Study: 21148048
Drug: Arterolane maleate
Normalized name: maleate
DrugBank: Arterolane (DB19027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arterolane maleate 200 mg
Study: 21148048
Drug: Combination with
Normalized name: Iron in combination with folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination with piperaquine phosphate
Study: 16440537
Drug: Multifamily Asthma
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifamily Asthma Group Treatment (MFAGT)
Study: 9222805
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg twice a day for ten days
Study: 9222805
Drug: Doxycycline plus
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline plus ceftriaxone (1 g in two doses for one day)
Study: 29231617
Drug: Medication combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication combined with acupuncture
Study: 25420776
Drug: Gestrinone combined
Normalized name: gestrinone
DrugBank: Gestrinone (DB11619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone combined with ultrasound-guided aspiration and ethanol injection
Study: 25420776
Drug: Ultrasound-guided aspiration
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided aspiration and ethanol injection